Bio-Rad Laboratories, Inc. (BIO) Management on Q2 2022 Results - Earnings Call Transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q2 2022 Earnings Conference Call July 28, 2022 6:00 PM ET

Company Participants

Edward Chung - Head of Investor Relations

Ilan Daskal - Executive Vice President & Chief Financial Officer

Andy Last - Executive Vice President & Chief Operating Officer

Simon May - President of Life Science Group

Dara Wright - President of Clinical Diagnostics Group

Conference Call Participants

Patrick Donnelly - Citi

Jack Meehan - Nephron Research

Operator

Good afternoon. Thank you for attending today's Bio-Rad Second Quarter 2022 Earnings Results Conference Call. My name is Hannah and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call, with an opportunity for questions and answers at the end [Operator Instructions].

I would now like to pass the conference over to our host Edward Chung, Head of Investor Relations. Please go ahead.

Edward Chung

Thanks, operator. Good afternoon and thank you for joining us. Today we will review the second quarter 2022 financial results and provide an update on key business trends for Bio-Rad. With me on the phone today are Norman Schwartz, our Chief Executive Officer; Ilan Daskal, Executive Vice President and Chief Financial Officer; Andy Last, Executive Vice President and Chief Operating Officer; Simon May, President of the Life Science Group; and Dara Wright, President of the Clinical Diagnostics Group.

Before we begin our review, I would like to caution everyone that we will be making forward-looking statements in our management's goals, plans and expectations, our future financial performance and other matters.

These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Included in these forward-looking statements are commentary regarding the impact of the COVID-19 pandemic on Bio-Rad's results and operations and steps Bio-Rad is taking in response to the pandemic.

Our actual results may differ materially from these plans and expectations and the impact and duration of the COVID-19 pandemic is unknown. You should not place undue reliance on these forward-looking statements and I encourage you to review our filings with the SEC, where we discuss in detail the risk factors in our business. The company does not intend to update any forward-looking statements made during the call today.

Finally, our remarks today will include references to non-GAAP net income and diluted earnings per share, which are financial measures that are not defined under Generally Accepted Accounting Principles. Investors should review the reconciliation of these non-GAAP measures to the comparable GAAP results contained in our earnings release.